For how we live.
The 2024 American Academy of Sleep Medicine guideline strongly backs intravenous iron and gabapentinoids, and now suggests against the dopamine agonists that were first-line for two decades.
The 2024 AASM guideline now advises against routinely using the dopamine agonists that were once standard, because over time they often make the condition worse — and puts anticonvulsants and iron first.
One in five people get chronic itch at some point. When no rash and no cause turn up, a Cochrane review found almost no trials at all — leaving guideline experts to work from indirect evidence.